Novo Nordisk STEP YOUNG Phase 3 trial met primary endpoint in children
Novo Nordisk reported that its STEP YOUNG Phase 3 trial met its primary endpoint, with 40.4% of children achieving BMI below the obesity threshold and no new safety concerns for semaglutide in children.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@blckchaindaily
🚨 NOVO NORDISK $NVO: 40.4% OF CHILDREN ACHIEVED BMI BELOW OBESITY THRESHOLD IN STEP YOUNG TRIAL
@BlockchainPill
The internet-computer:native downtrend line happened to be at the PoC for the entire range since Oct 10th liquidation event That's the average price where most of the internet-computer:native volume happened this entire period Now that the PoC was reclaimed, a full value https://t.co/WDl6xd6Lzr
@blckchaindaily
🚨 NOVO NORDISK $NVO SAYS STEP YOUNG PHASE 3 TRIAL MET PRIMARY ENDPOINT